Press release
United States Primary Biliary Cholangitis Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities
Primary Biliary Cholangitis Treatment Market
The Global Primary Biliary Cholangitis Treatment Market reached US$ 1.33 billion in 2024 and is expected to reach US$ 2.72 billion by 2033, growing at a CAGR of 7.8 % during the forecast period of 2025-2033.
Recent Mergers and Acquisitions
United States: Recent M&A Developments
✅ In March 2025, Sun Pharmaceutical Industries (India) announced the acquisition of U.S.-based Checkpoint Therapeutics for USD 355 million, gaining entry to its immunotherapy and oncology portfolio and strengthening its North American presence.
✅ In February 2025, Bain Capital (USA) signed a definitive agreement to acquire Japan's Mitsubishi Tanabe Pharma Corporation for about USD 3.3 billion, marking a major cross-border life-sciences deal and expanding Bain's global pharma footprint.
✅ In February 2025, Novartis AG agreed to acquire Anthos Therapeutics (USA) in a transaction valued at up to USD 3.1 billion, gaining access to its late-stage cardiovascular and antithrombotic pipeline.
Japan: Recent M&A Developments
✅ In October 2025, Shionogi & Co., Ltd. resolved to merge its wholly-owned manufacturing subsidiary Shionogi Pharma Co., Ltd. into the parent company in a simplified absorption-type merger effective April 1 2027, as part of its global expansion strategy.
✅ In May 2025, Shionogi & Co., Ltd. announced a share-acquisition agreement to acquire 100 % of U.S.-based Akros Pharma Inc. for about USD 23.8 million, strengthening its overseas drug-development capabilities.
✅ In March 2025, Marubeni Corporation acquired a 60 % stake in a company taking over Sumitomo Pharma Co., Ltd.'s Asia pharmaceutical sales business for approximately JPY 45 billion, expanding its regional pharma footprint.
✅ In February 2025, Bain Capital (USA) moved to acquire Mitsubishi Tanabe Pharma (Japan) for ~USD 3.3 billion, enabling the Japanese firm to access global scale while Bain taps Japan's pharma innovation.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/primary-biliary-cholangitis-treatment-market?sb
Key Development:
United States: Recent Industry Developments
✅ In 2025, Gilead Sciences announced plans to present new clinical data and ongoing advancements in seladelpar for the treatment of Primary Biliary Cholangitis (PBC). The update reflects Gilead's continued commitment to developing novel therapies for rare liver diseases.
Japan: Recent Industry Developments
✅ In March 2025, a Phase III clinical study for elafibranor (80 mg) was initiated in Japan to assess its efficacy and safety among adult PBC patients. The trial aims to support local regulatory approval and improve access to advanced therapies.
✅ In March 2025, Kowa Company Ltd. launched a Phase II randomized, placebo-controlled clinical trial for pemafibrate (K-808) in PBC patients with an inadequate response to UDCA or OCA. The study underscores Japan's focus on innovative lipid-modulating treatments for liver disorders.
Key Players:
=> Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Ipsen Biopharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc., AbbVie Inc., Aden Healthcare., Zydus Therapeutics Inc., COUR Pharmaceuticals, Kowa Company, Ltd., Mirum Pharma, Parvus Therapeutics Inc, GSK plc., Strides Pharma Science Limited, and Calliditas Therapeutics AB. Among others.
Growth Forecast Projected:
The Global Primary Biliary Cholangitis Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Primary Biliary Cholangitis Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=primary-biliary-cholangitis-treatment-market
Key Segments:
➥ By Drug Type: Obeticholic Acid, Seladelpar, Elafibranor, Ursodeoxycholic Acid (UDCA), Others
➥ By Age Group: Adults, Geriatrics
Regional Analysis for Primary Biliary Cholangitis Treatment Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.
Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.
Chapter 3: Offers an in-depth look at the competitive landscape among Primary Biliary Cholangitis Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.
Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.
Chapters 5 & 6: Analyze Primary Biliary Cholangitis Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.
Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.
Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.
Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.
Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/primary-biliary-cholangitis-treatment-market?sb
FAQ
What is the current size of the Primary Biliary Cholangitis Treatment Market?
A: In 2024, the Primary Biliary Cholangitis Treatment Market was valued at US$ 1.33 billion , reflecting its strong industry presence.
Q2: How large is the Primary Biliary Cholangitis Treatment Market expected to be by 2033?
A: By 2033, industry forecasts suggest the Primary Biliary Cholangitis Treatment Market will grow to around US$ 2.72 billion, demonstrating significant expansion.
Q3: What is the growth rate of the Primary Biliary Cholangitis Treatment Market?
A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.8 % during the forecast period from 2025 to 2033.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Primary Biliary Cholangitis Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities here
News-ID: 4257340 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Localized Scleroderma Market to hit US$ 43.91 Billion by 2031 | To …
"Global Non-Meat Ingredients Market reached US$ 31.12 billion in 2022 and is expected to reach US$ 43.91 billion by 2031, growing with a CAGR of 4.4% during the forecast period 2024-2031." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/localized-scleroderma-market?sp
United States: Recent Industry Developments
✅ In November 2025, Horizon Therapeutics launched a new clinical trial evaluating IL-6 inhibitor therapy for localized scleroderma, aiming…
United States Flavonoid Glycosides Market to hit US$ 640.6 Million by 2031 | Top …
"Global Flavonoid Glycosides Market reached US$ 387.1 million in 2023 and is expected to reach US$ 640.6 million by 2031, growing with a CAGR of 6.5% during the forecast period 2024-2031." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/flavonoid-glycosides-market?sp
United States: Recent Industry Developments
✅ In November 2025, Chr. Hansen Inc. launched a high-purity flavonoid glycoside extract for dietary supplements and functional beverages,…
United States Prosthetic Contact Lenses Market expected to grow at a CAGR during …
"U.S. Prosthetic Contact Lenses Market reached US$ billion in 2023 and is expected to reach US$ million by 2031 growing at a CAGR during the forecast period 2024-2031." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/united-states-prosthetic-contact-lenses-market?sp
United States: Recent Industry Developments
✅ In November 2025, EyePrintPROTM by Miami Contact Lens Institute expanded its custom scleral cover‐shell lens service nationwide, offering highly individualised…
United States Peripheral Vascular Clot Management Interventions Market 2025 | Gr …
Market Size and Growth
Global Peripheral Vascular Clot Management Interventions Market is expected to reach at a high CAGR during the forecast period 2023-2030.
Key Development & Recent Mergers and Acquisitions:
United States: Recent Industry Developments
✅ In October 2025, Inquis Medical's AVENTUS Thrombectomy System received expanded clearance from the U.S. Food & Drug Administration (FDA) for treatment of pulmonary embolism after earlier clearance for the peripheral vasculature. The platform features integrated tissue‐sensing…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
